Batroxobin - Lee's Pharmaceutical

Drug Profile

Batroxobin - Lee's Pharmaceutical

Alternative Names: Haemocoagulase - Lee's Pharmaceutical; Slounase; Snake venom thrombin- Lee's Pharmaceutical

Latest Information Update: 06 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lees Pharmaceutical Holdings
  • Class Coagulants; Crotalid venoms; Serine endopeptidases
  • Mechanism of Action Fibrinogen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Blood coagulation disorders
  • Clinical Phase Unknown Lung disorders

Most Recent Events

  • 06 Jun 2017 Clinical trials in Lung disorders in China (Parenteral) (NCT03270735)
  • 14 Oct 2005 Launched for Coagulation disorders in China (Parenteral)
  • 14 Oct 2005 Registered for Coagulation disorders in China (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top